Agents that target specific peptides having key roles in osteoblast formation or osteoclast function, leading up to several promising candidates, will be potential future compounds to become effective antiresorptive
or anabolic agents to treat osteoporosis.
The objective of the study was to test the effects of antiresorptive
osteoporosis drug alendronate 70 mg weekly on symptoms of knee osteoarthritis with the prior hypothesis that biphosphonates may have disease modifying effects on knee osteoarthritis consequently would decrease the symptoms from initial of treatment.
Although the mechanism of action is not fully understood, calcium, vitamin D and antiresorptive
agents are recommended in the treatment of PPSO (1), (3), (8), (15).
Claes Ohlsson, Sweden Rationale for Choosing Anabolic or Antiresorptive
Instead, the clear message from this and several other sources is that biochemical markers of bone turnover/remodeling are very effective tools for monitoring the effectiveness of antiresorptive
therapy in individual patients as well as in groups of patients.
The issue of combination therapy with parathyroid hormone plus antiresorptive
drugs is of particular interest to clinicians.
Now, according to the results of a two-year pilot study conducted by a team of Australian researchers led by Brian Gulson of Macquarie University, antiresorptive
therapy may also be useful in warding off the deleterious health effects of elevated blood lead levels by inhibiting lead's release from the skeleton into the bloodstream [EHP 110:1017-1023].
class of drugs is by far the largest in the market, accounting for an estimated 90% of the total sales in 2010.
AB-25E9, a first-in-class bone antiresorptive
monoclonal antibody with a novel mechanism of action that is being developed for the treatment of bone loss in oncology indications such as multiple myeloma and invasive carcinomas.
MINNEAPOLIS--Combining the antiresorptive
drug deno-sumab with the anabolic agent teriparatide increased bone mineral density more than either drug alone in postmenopausal women at high fracture risk in the ongoing DATA study.
therapies reduce osteoclast activity but most also impair bone formation.
Likely we'll use sclerostin therapy for a relatively short time--6 months, 12 months--followed by probably another drug, like an antiresorptive
drug, and then attempt to take advantage of that first burst of anabolic activity again.